TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03053154

Intervention type: OTHER
Intervention: Sagittal pelvic tilt assessment
Description: Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.

Intervention type: OTHER
Intervention: Sagittal pelvic tilt assessment
Description: Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.

Intervention type: OTHER
Intervention: Sagittal pelvic tilt assessment
Description: Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.
Study: NCT01326754

Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine combination
Description: Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days

Intervention type: DRUG
Group type: OTHER
Intervention: Artesunate-amodiaquine combination
Description: Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days

Intervention type: DRUG
Group type: OTHER
Intervention: Dihydroartemisinin-piperaquine
Description: Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
Study: NCT03856554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Transforaminal Interbody fusion
Description: TLIF via unilateral factectomy and insertion of one cage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Transforaminal Interbody fusion
Description: TLIF via bilateral factectomy and insertion of two cages
Study: NCT01535560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-60371, 0.3% otic suspension
Description: Investigational otic suspension intended for the treatment of acute otitis externa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-60371 Vehicle
Description: Inactive ingredients used as placebo
Study: NCT03019731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-directed Behavioral Therapy
Description: The therapist-directed behavioral therapy group will have their first appointment scheduled within one week of assignment. In the Therapist-directed face-face training program, training instructions will be manualized, in order to match the parent instructional guidelines provided in the home-based DVD. This manual will include the specific psychoeducation, awareness training, competing response training, differential reinforcement of incompatible behaviors, and other adaptive behavioral instructions contained within the home-based DVD. The therapist will match the sequence and required components within the behavior-based training DVD. Face-face training will be administered across 10 weeks (6 weekly sessions followed by 2 bi-weekly sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based DVD Therapy
Description: In order to mimic the slight delay between randomization and start of the therapist-directed treatment, those assigned to the Home-based DVD cohort will have the DVD and training materials mailed to their homes. Parents will also receive a written instructional form and a log sheet for tracking the use of the DVD and the time and duration of practice sessions. Any questions regarding patient care and treatment will be directed to Dr. Singer.
Study: NCT02009761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection
Study: NCT02596165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse wave analysis measurement with Schiller BR-102 Plus PWA device
Description: Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
Study: NCT04379726

Intervention type: BEHAVIORAL
Intervention: therapeutic optimization
Description: patients with diagnosis of CFRD will undergo the gold standard treatment for the disease (insulin therapy)
Study: NCT01598623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: three times a week for three weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: three times a week for three weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Non Specific Counselling
Study: NCT01815138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
Study: NCT03770533

Intervention type: OTHER
Group type: OTHER
Intervention: MR-proADM guided
Description: MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized
Study: NCT02647216

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Cognitive Therapy
Description: Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
Study: NCT02538510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02647216

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
Study: NCT02538510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO or via PEG
Study: NCT06596720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: After the initial assessments of the individuals in the study group were completed, the exercise program was implemented. The exercise program consisted of 30 minutes of submaximal cycling using the Karvonen formula. The aerobic exercise program was structured with a 5-minute warm-up, a 5-minute cool-down, and the remaining time dedicated to the exercise phase. Since our study included only a single exercise session, a moderate-intensity training program was applied to the participants.
Study: NCT02328339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to tea with respect to taste and appearance
Study: NCT02335528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SimCoach
Study: NCT04307420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonic Fill Restoration
Description: Kerr's Sonic Fill is the only sonic-activated, single-step, bulk-fill composite that starts out as a low-viscosity composite.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Composite Resin Restoration
Description: Composite resins are polymer-based materials used in dentistry for aesthetic repairs.Polymerization is accomplished typically with a hand held curing light that emits specific wavelengths keyed to the initiator and catalyst packages involved.
Study: NCT02708914

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: UB-851
Description: UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: UB-851
Description: UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Eprex
Description: Eprex® is chosen as the comparator.
Study: NCT00622258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolmus
Study: NCT00804089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional needle acupuncture
Description: Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial trigger point dry needling
Description: Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial trigger point acupressure
Description: Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
Study: NCT04137094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive Health Communication Intervention
Description: A persuasive health communication intervention will be performed

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive Health Communication Intervention
Description: A persuasive health communication intervention will be performed
Study: NCT00650351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin Extended-Release Tablets 1000 mg
Description: 1000mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipro® XR Tablets 1000 mg
Description: 1000mg, single dose fed
Study: NCT04552483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
Study: NCT02876276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid filler
Description: Papillary augmentation with HA dermal fillers was considered as the test group

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid filler
Description: Papillary augmentation with HA dermal fillers was considered as the test group
Study: NCT00645047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine CBT
Description: Use of Videoconfrence Technology To Provide Cognitive Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person CBT
Description: In-Person Provision Of Cognitive Therapy
Study: NCT03219515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gongjin-Dan
Description: Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
Study: NCT03002753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: detached mindfulness
Description: Please see detailed study description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive restructuring
Description: Please see detailed study description.
Study: NCT01091077

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Naringenin
Description: 1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
Study: NCT03125720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Image fusion of SPECT MPI and fluoroscopy venography
Description: In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
Study: NCT01981395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenobam
Description: Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
Study: NCT03402490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Study: NCT00557180

Intervention type: DRUG
Intervention: Beclomethasone dipropionate HFA
Description: Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation

Intervention type: DRUG
Intervention: Tiotropium bromide
Description: Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
Study: NCT06601855

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy, whether open or laparoscopic
Study: NCT00557180

Intervention type: DRUG
Intervention: Salmeterol xinafoate
Description: Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
Study: NCT04054518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
Study: NCT04467528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Experimental: Electroacupuncture combined with conventional drug therapy~Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial~For participants with abdominal distension:~Electroacupuncture will be applied to the acupoints (LI4, PC6, ST36, SP6) 30min~For participants with post-operative ileus:~Electroacupuncture will be applied to the acupoints (LI4, SJ6, ST36, ST37) 30min~32# acupuncture needle used and twice daily for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drug therapy
Description: Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy
Description: Conventional drug therapy:~All participants receive intravenous infusion of metoclopramide(10mg) every 12 hours in the trial
Study: NCT04435210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses
Study: NCT01322997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myomo e100 Robot and repetitive task specific training
Description: Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive task specific training (RTP) targeting the affected arm
Description: Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myomo e100 neurorobotic brace
Description: Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
Study: NCT01810601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRh, HMG, HCG, Progesterone
Description: GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GnRh, HMG, HCG, Progesterone
Description: GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
Study: NCT03753737

Intervention type: OTHER
Intervention: Questionnaires and semi-structured interview
Description: * Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~* Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder.

Intervention type: OTHER
Intervention: Questionnaires and semi-structured interview
Description: * Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~* Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder.
Study: NCT03868605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMR and ESD
Description: Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over- the- scope full- thickness resection device
Description: Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device
Study: NCT02926404

Intervention type: DEVICE
Intervention: UNiD Rods
Description: Spinal osteosynthesis

Intervention type: DEVICE
Intervention: UNiD Rods
Description: Spinal osteosynthesis
Study: NCT01330173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02776384

Intervention type: OTHER
Intervention: Observational study
Study: NCT01582685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
Study: NCT03154073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Exercise Training (MOD)
Description: For the first 4 weeks, participant will be asked to complete 3 days of exercise/week at 50-65% heart rate maximum. Sessions will last between 30-40 minutes excluding the warm-up and cool down (5-10 minutes). After 4 weeks, the MOD group will be expected to match the exercise prescription. The exercise prescription for the MOD group for weeks 5-12 will be 4 days/week, 45 min/session completed at 60-65% heart rate maximum.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous Intensity Exercise Training (VIG)
Description: The exercise lead in period will be the same as the moderate intensity exercise training program. After 6 weeks, the VIG group will be expected to match the exercise prescription. The exercise prescription for the VIG for weeks 7-12 will be 4 days/week, 45 min/session completed at 80-85% heart rate maximum.
Study: NCT03866473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retilux
Description: 670nm wavelength light

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Light Device
Description: Broad spectrum light device
Study: NCT00682773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SBAR
Description: Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
Study: NCT01049932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278LA
Description: TMC278LA 600mg injected intramuscularly (i/m)
Study: NCT05131568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Layered thermal insulation system
Description: No other intervention
Study: NCT02637570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hibiscus tea

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hibiscus tea

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: green tea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo (dextrose)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo (dextrose)
Study: NCT01165931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: 0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).